The risk reduction ( and therefore potential cost savings ) in this subgroup is dramatic . The event lines separate very early and separation is very evident at the 3 yr pt. Yes we would need buy end to some extent from the Health Depts in Germany , France and Italy.
My understanding is that CAD patients are a lot more adherent to taking their meds after being admitted for a CV event . Recruiting should be a lot easier and quicker then R-IT since theres a lot of followup with these patients in the first months following a PCI
Capt. I linked data from the supplemental section of the Revasc analysis but it didn't format easily ....If you look you will see a dramatic reduction in needing a repeat revascularisation for those on Vascepa Kiwi
You are correct, and kiwi continues to be out to lunch in failing to acknowledge a line in one of DMC8’s links today that the Vascepa market is being retained because freedom from pancreatitis has not been shown by a generic clinical trial. The generics have the burden of proof.
News 
Market Data 
Discover 
